PL3891138T3 - Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu - Google Patents

Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu

Info

Publication number
PL3891138T3
PL3891138T3 PL21707628T PL21707628T PL3891138T3 PL 3891138 T3 PL3891138 T3 PL 3891138T3 PL 21707628 T PL21707628 T PL 21707628T PL 21707628 T PL21707628 T PL 21707628T PL 3891138 T3 PL3891138 T3 PL 3891138T3
Authority
PL
Poland
Prior art keywords
targeted delivery
activation protein
fibroblast activation
delivery applications
protein ligands
Prior art date
Application number
PL21707628T
Other languages
English (en)
Inventor
Ilaria BIANCOFIORE
Samuele CAZZAMALLI
Sheila Dakhel Plaza
Etienne J. DONCKELE
Jacopo MILLUL
Florent SAMAIN
Eleonore SCHMIDT
Original Assignee
Philochem Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philochem Ag filed Critical Philochem Ag
Publication of PL3891138T3 publication Critical patent/PL3891138T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL21707628T 2020-02-12 2021-02-12 Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu PL3891138T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20157036 2020-02-12
EP20172953 2020-05-05
EP20202856 2020-10-20
PCT/EP2021/053494 WO2021160825A1 (en) 2020-02-12 2021-02-12 Fibroblast activation protein ligands for targeted delivery applications
EP21707628.0A EP3891138B1 (en) 2020-02-12 2021-02-12 Fibroblast activation protein ligands for targeted delivery applications

Publications (1)

Publication Number Publication Date
PL3891138T3 true PL3891138T3 (pl) 2022-05-02

Family

ID=74701462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21707628T PL3891138T3 (pl) 2020-02-12 2021-02-12 Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu

Country Status (6)

Country Link
EP (2) EP3891138B1 (pl)
DK (1) DK3891138T3 (pl)
ES (1) ES2910941T3 (pl)
HU (1) HUE058835T2 (pl)
PL (1) PL3891138T3 (pl)
WO (1) WO2021160825A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016392A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use
EP4043452A1 (en) * 2021-02-12 2022-08-17 Philochem AG Bivalent fibroblast activation protein ligands for targeted delivery applications
CN113880810B (zh) * 2021-09-24 2023-02-28 厦门大学 一种核素标记的配合物及其制备方法和应用
CN113880811B (zh) * 2021-09-29 2022-09-02 厦门大学附属第一医院 Fapi二聚体化合物、基于fapi二聚体的肿瘤诊断pet显像剂及其制备方法和应用
MX2024004077A (es) * 2021-10-04 2024-04-18 Philochem Ag Ligandos de proteina de activacion de fibroblastos radioetiquetados.
DE102021133942A1 (de) * 2021-12-20 2023-06-22 Atoms for Cure GmbH FAP-adressierendes Pharmazeutikum für die Therapie und Diagnose von Krebserkrankungen
CN116554146A (zh) * 2022-01-29 2023-08-08 中国科学院生物物理研究所 一种FAP-α特异性放射性药物及其应用
US20250177582A1 (en) 2022-01-30 2025-06-05 Philochem Ag High-affinity ligands of fibroblast activation protein for targeted delivery applications
CN115304582B (zh) * 2022-07-20 2023-05-12 北京法伯新天医药科技有限公司 FAP-α特异性肿瘤诊断显像剂
WO2024022332A1 (en) * 2022-07-26 2024-02-01 Shanghai Sinotau Biotech. Co., Ltd Fap inhibitors
CN119816493A (zh) * 2022-09-06 2025-04-11 菲罗化学股份公司 用于靶向递送应用的多价成纤维细胞激活蛋白配体
EP4342890A1 (en) 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
AU2023347470A1 (en) 2022-09-23 2025-04-10 Nuclidium Ag High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
TW202426433A (zh) * 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
CN117883585A (zh) * 2022-10-14 2024-04-16 无锡诺宇医药科技有限公司 靶向成纤维细胞活化蛋白的药物及其应用
WO2024197111A2 (en) * 2023-03-22 2024-09-26 Regents Of The University Of Michigan Radiolabeled fibroblast activation protein inhibitors and methods of making same
KR102924988B1 (ko) * 2023-07-04 2026-02-06 이화여자대학교 산학협력단 화합물, 이를 포함한 조성물 및 이를 이용한 광역학 진단 또는 치료 방법
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025063849A2 (en) 2023-09-21 2025-03-27 Erasmus University Medical Center Rotterdam Dimeric fap targeting agents
WO2025125335A1 (en) * 2023-12-13 2025-06-19 Radiovaxx Gmbh Cytotoxic or radiopharmaceutical compound with sulfur fluoride exchange group
WO2026010658A2 (en) * 2024-03-22 2026-01-08 Nuclidium Ag Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof
WO2025250709A1 (en) * 2024-05-28 2025-12-04 Actithera, Inc. Bifunctional compounds for cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1729774A4 (en) 2004-03-09 2009-05-06 Nat Health Research Institutes PYRROLIDINE CONNECTIONS
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
JP2021506972A (ja) 2017-12-15 2021-02-22 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
SG11202007180QA (en) 2018-02-06 2020-08-28 Univ Heidelberg Fap inhibitor

Also Published As

Publication number Publication date
DK3891138T3 (da) 2022-04-04
HUE058835T2 (hu) 2022-09-28
ES2910941T3 (es) 2022-05-17
EP3891138A1 (en) 2021-10-13
EP3891138B1 (en) 2022-01-12
WO2021160825A1 (en) 2021-08-19
EP4019507A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
PL3891138T3 (pl) Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu
IL292113A (en) Bicyclic drug ligand conjugates
SI3997103T1 (sl) Spojine, ki obsegajo ligand proteina za aktiviranje fibroblastov in uporaba le teh
IL311694A (en) A radiolabeled fibroblast activation protein ligand
IL289673A (en) Compounds comprising a fibroblast activation protein ligand and use thereof
IL276784A (en) Drug delivery systems
IL284434A (en) Fibroblast activation protein inhibitors
CA3266566A1 (en) MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
EP3712179A4 (en) BINDING UNIT DIRECTED AGAINST FIBROBLAST ACTIVATION PROTEIN ALPHA AND APPLICATION OF IT
GB202004701D0 (en) Delivery system
EP4340619A4 (en) MODIFIED ANTIMICROBIAL PEPTIDES
GB202008130D0 (en) Delivery system
HK40102910A (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
EP3515466A4 (en) OPTIMIZED SYNTHETIC INMUNOGENOUS CONSENSUS COMPOSITIONS AGAINST FIBROBLAST ACTIVATION PROTEIN
GB202008120D0 (en) Delivery system
GB202004730D0 (en) Delivery system
GB202004707D0 (en) Delivery system
WO2024049961A9 (en) Treatment for ovarian cancer with oligonucleotides targeting fibroblast activation protein alpha
PT3997103T (pt) Compostos que compreendem um ligando da proteína de ativação de fibroblastos e sua utilização
GB202110820D0 (en) Targeted protein degradation
GB201914875D0 (en) Bicyclic peptide ligand drug conjugates
GB201914196D0 (en) Bicyclic peptide ligand Drug conjugates
GB201914194D0 (en) Bicyclic peptide ligand drug conjugates
GB202114282D0 (en) Bicyclic peptide ligand drug conjugates
GB202114279D0 (en) Bicyclic peptide ligand drug conjugates